Senior Management Team

Mr. Crowley became president and CEO of Amicus in January 2005 and was appointed Chairman of the Board in February 2010. Previously he was founding president and CEO of Orexigen Therapeutics. Preceding Orexigen, Mr. Crowley was senior vice president at Genzyme Therapeutics, a position he assumed after overseeing the sale of Novazyme Pharmaceuticals to Genzyme in September 2001. Mr. Crowley was the founding president and CEO of Novazyme that was developing a novel treatment for Pompe disease. He previously served in several senior management roles with the Bristol-Myers Squibb Company (BMS), including director of the Executive Committee for the U.S. Medicines Group, director of Business Strategy for the U.S. Pharmaceuticals Group, and director of U.S. Area Marketing for the Neuroscience and Infectious Disease Division. Preceding his experience at BMS, Mr. Crowley worked as a business strategy consultant for Marakon Associates. Mr. Crowley began his professional career as a litigation associate in the Health Care Practice Group of the Indianapolis-based law firm of Bingham, Summers, Welsh & Spilman.

Mr. Crowley is involved with several charitable and community organizations, including serving on the Board of Directors of St. Peter's University Health Care System. Mr. Crowley's involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease - a fatal neuromuscular disorder. Mr. Crowley and his family have been featured on the cover of The Wall Street Journal and on The Today Show, CNBC and The Paula Zahn Show on CNN. In 2006, Geeta Anand, Pulitzer prize winning writer for The Wall Street Journal, authored a book on Mr. Crowley entitled "The Cure: How a Father Raised $100 Million- and Bucked the Medical Establishment- in a Quest to Save His Children." (www.thecurebook.com).

Mr. Crowley is a commissioned officer in the United States Navy Reserve (active).

Mr. Crowley earned his B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, his J.D. from the University of Notre Dame Law School and his M.B.A. from Harvard Business School.

Mr. Patterson joined Amicus in December 2004 and currently serves as Chief Operating Officer. Mr. Patterson was promoted to Chief Operating Officer from Chief Business Officer in September 2006. Prior to Amicus, Mr. Patterson served as vice president of Regulatory Affairs, and later vice president of Commercial Planning at BioMarin Pharmaceutical. Mr. Patterson oversaw the development of Aldurazyme® (laronidase) for the treatment of the genetic disease MPS I and helped build the sales and marketing function for the company. Prior to BioMarin, Mr. Patterson worked at Genzyme Corporation in Manufacturing and Regulatory Affairs. While at Genzyme he contributed to the development and global licensing of multiple products.

Matt is a member of the Board of Directors of Gilda's Club of New York City, which provides social and emotional support for people living with cancer.

Mr. Patterson received his B.A. in Biochemistry from Bowdoin College.

Dr. David Lockhart joined Amicus Therapeutics in January 2006 as chief scientific officer. He brings to Amicus 13 years of industry experience and achievements including credit as the primary developer of genome-wide gene-expression profiling with high-density DNA arrays when he was at Affymetrix.

Before coming to Amicus, Dr. Lockhart was president, CSO and co-founder of Ambit Biosciences in San Diego. He has served as director of genomics at the Genomics Institute of the Novartis Research Foundation, and he held various leadership positions during his more than five years at Affymetrix, including vice president of genomics research. Dr. Lockhart has also been a visiting scholar at the Salk Institute for Biological Studies.

Dr. Lockhart received his Ph.D. in Chemistry from Stanford University and was a postdoctoral fellow at the Whitehead Institute at MIT under Professor Peter S. Kim. He has published nearly 60 peer-reviewed scientific articles on kinase technology, kinase inhibitor discovery, genomics and the use of genomic tools for important biological and biomedical problems.

Dr. Pol Boudes joined Amicus Therapeutics in January 2009 as Chief Medical Officer. He brings to Amicus more than 15 years of industry experience in clinical drug development. Dr. Boudes was instrumental in obtaining registration for multiple drugs in the field of Women's Health, Osteoporosis, Dermatology, and AIDS/HIV infection, both in the U.S. and ex-U.S.

Prior to Amicus, between January 2004 and January 2009, Dr Boudes was with Bayer HealthCare Pharmaceuticals following its merger with Berlex. Most recently he was Vice President, global clinical development Women's Health Care US. Prior to Berlex, from 1990 to 2004, Dr. Boudes served in positions of increasing responsibility with the Wyeth-Ayerst Research division of Wyeth both in Philadelphia, PA and in Europe, with Hoffmann-La Roche, and with Pasteur-Merieux serums & vaccines (now part of Sanofi-Aventis).

Dr. Boudes received his M.D. from the University of Aix-Marseilles, France. He completed his internship and residency in Marseilles and in Paris, France and was an Assistant Professor of Medicine at the University of Paris. He is specialized in Endocrinology and Metabolic Diseases, Internal Medicine, and Geriatric diseases. He practiced medicine in this capacity in academic hospitals in France where he also participated in multiple clinical research programs as an investigator.

Dr. Boudes has published more than 50 papers in peer-reviewed medical journals, notably in the field of clinical drug development. He holds several records of invention.

Geoffrey P. Gilmore joined Amicus Therapeutics in March 2008 as Senior Vice President, General Counsel and Secretary. Prior to joining Amicus, from 2003 to 2008, Mr. Gilmore was in the Law Department at Bristol-Myers Squibb Company, where most recently he served as Vice President and Senior Counsel. During his time at Bristol-Myers Squibb, he managed the company's pharmaceutical research and development legal group, the corporate securities legal group and supported the Corporate Secretary function. From 2002 to 2003, Mr. Gilmore was a Senior Attorney at Wyeth Pharmaceuticals where he focused on pharmaceutical regulatory law. From 1997 to 2002, Mr. Gilmore held various positions in the law department of Bristol Myers Squibb Company supporting the company's sales and marketing operations and working in the intellectual property group. Prior to joining Bristol-Myers Squibb Company, Mr. Gilmore worked at the law firms, Ballard Spahr Andrews & Ingersoll, LLP, where he practiced in the Business and Finance Group, and Montgomery, McCracken, Walker & Rhoads, LLP, where he practiced in the Corporate & Securities Group.

Mr. Gilmore received his B.A. from Franklin and Marshall College, and his J.D. from University of Michigan Law School.

Nicole Schaeffer has overseen Human Resources and Leadership Development at Amicus since March 2005. She brings over eight years of experience building talent at early stage biotechnology companies. Prior to joining Amicus, Ms. Schaeffer worked at Flagship Ventures helping to start several high-tech/biotech companies including Adnexus Therapeutics, Epitome Biosystems and BG Medicine.

Ms. Schaeffer served as Director and later Senior Director of Human Resources for all three firms, responsible for all HR functions. Preceding her work with Flagship Ventures, Ms. Schaeffer rose from Manager to Director of Human Resources, responsible for all HR functions for Oak Industries, Inc., a publicly traded $450 million supplier of components to the communications industry. During her tenure, Oak Industries was acquired by Corning Inc. Ms. Schaeffer has also held a variety of human resources positions at EMC Corporation.

Ms. Schaeffer received her B.A. from the University of Rochester and her M.B.A. from Boston University.

Mr. McAdam joined Amicus in March 2006, and he currently serves as Vice President, Finance and Accounting, Principal Financial and Accounting Officer, and Treasurer. Mr. McAdam has previously served as the Company's Corporate Controller and from March 2006 to September 2006 served as the Company's Interim Principal Financial and Accounting Officer. Prior to joining Amicus, from 2001 to 2006, Mr. McAdam worked at Quest Diagnostics Incorporated where he served in a variety of financial positions, most recently as Director of Accounting and Reporting. Mr. McAdam has also worked as an audit professional at KPMG LLP. Mr. McAdam is a certified public accountant and received his B.S. in Accountancy from Villanova University and his M.B.A. from Rutgers Business School.

Mr. Campbell joined Amicus in May 2006, and he currently serves as Vice President, Business Operations, overseeing program management, business development and commercial planning. Prior to Amicus, Mr. Campbell was the Business Director of Genzyme Cardiovascular, responsible for business development, alliance management and commercial planning for cardiac gene therapy programs. Previously, he was Sr. Product Manager for Myozyme®, Genzyme's enzyme replacement therapy for Pompe disease.

Mr. Campbell has also worked in sales & marketing for Bristol-Myers Squibb, and as a business strategy consultant for Marakon Associates. He is active in a number of philanthropic organizations and is a Past-President and current Executive Committee member of the Board of Directors of the National Tay-Sachs and Allied Diseases Association.

Mr. Campbell received his B.A. in Public Policy Studies from Duke University and his M.B.A. from Harvard Business School.

John Kirk joined Amicus Therapeutics in January 2008 as Vice President of Regulatory Affairs. John brings over 20 years of experience in Regulatory Affairs and has a proven track record in large scale, international regulatory issues and product approvals. Mr. Kirk was most recently Executive Director, Regulatory Affairs at Aegerion Pharmaceuticals and Director, Worldwide Regulatory Affairs at Pfizer Global Research & Development. In these positions John played a key role in several programs in the cardiovascular and inflammation therapeutic areas. Prior to Pfizer, John served as Senior Director, Regulatory Affairs at Esperion Therapeutics. Esperion was developing late stage compounds designed to mimic or enhance the reverse cholesterol transport function of HDL when it was acquired by Pfizer in 2003. At Esperion, John played a key role in the development and execution of regulatory strategies for these important developmental compounds. He brings significant expertise in several cardiovascular and metabolic related areas and has proven ability to contribute to the growth of early stage pharmaceutical companies as well as understanding U.S. and international regulatory processes required to create global registration strategies.